Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: The confirmation hearing of Ronny Jackson, Trump’s White House doctor and a Navy rear admiral chosen to speed up improvements to the VA, is scheduled for next week. On Tuesday, he met privately with Sen. Jon Tester of Montana, the top Democrat on the Senate Veterans Affairs Committee, as a part of visits this week to assure lawmakers he could effectively lead the government’s second-largest department. Tester said after the meeting that Jackson had committed to the same stance against privatization as David Shulkin, who pledged before his confirmation as VA secretary last year to continue strong investment in core VA programs and facilities while expanding access to private doctors. Shulkin was fired last month. “We talked extensively about why Shulkin got fired with the issues revolving around privatization and capacity building,” Tester said. He “seems to be somebody who doesn’t want to privatize the VA.” Asked if Jackson had pledged not to privatize VA, Tester said “yes.” “He said basically the same thing Shulkin said--that he wanted to build capacity at the VA,” Tester said. According to Tester, Jackson had not yet informed Trump of his views but would be doing so. Both Tester and Sen. Johnny Isakson, the Republican chairman of the veterans committee who met with Jackson Monday, have declined to endorse Jackson in advance of his confirmation hearing on April 25, saying they need to hear more about his plans to fix VA. Jackson is “certainly not an expert on VA,” Tester said. Sen. Patty Murray, D-Wash., a Senate committee member who also met Tuesday with Jackson, said she needed more assurances that Jackson would resist undue White House pressure to aggressively expand private care. Major veterans groups view VA medical centers as best suited to treat complex battlefield injuries, such as traumatic brain injury. “In our meeting today, I appreciated how strongly Dr. Jackson spoke against privatizing the VA, but I still need to know more about how he will stand up to ideological opponents of VA and remain fully committed to putting the needs of veterans first,” Murray said. The issue of privatizing VA has been a political hot button since the 2016 campaign, when Trump pledged to aggressively expand veterans’ access to private doctors outside the government-run VA system at taxpayers’ expense via the Veterans Choice program. Trump’s comments came in the wake of a 2014 scandal at the Phoenix VA medical center in which some veterans died while waiting months for medical appointments. After he was fired as VA secretary, Shulkin blamed “political forces” in the Trump administration that he says are bent on privatizing the agency and prioritizing “companies with profits” over the care of veterans. On Tuesday, the White House reiterated that there were “no discussions” about privatizing VA. “This administration has taken several unprecedented steps to transform and modernize the VA,” White House spokesman Raj Shah said in a statement. “We look forward to continuing our work with Congress to reform and strengthen the VA Choice program to provide our veterans with more choice in their health care.” Several Democratic senators, including Bernie Sanders of Vermont, a member of the Senate Veterans Affairs Committee, have vowed to oppose Jackson’s nomination if it leads to greater privatization at the agency. Before he was confirmed last year as VA secretary, Shulkin, a holdover from the Obama administration, declared in advance that he wouldn’t “privatize” VA. “VA is a unique national resource that is worth saving, and I am committed to doing just that,” Shulkin said in February 2017. “There will be far greater accountability, dramatically improved access, responsiveness and expanded care options, but the Department of Veterans Affairs will not be privatized under my watch.” ___ Follow Hope Yen on Twitter at https://twitter.com/hopeyen1 Claim: Dem senator: Trump VA pick vows not to privatize vets care.

Ex Output:
President Donald Trump’s pick to be Veterans Affairs secretary is promising not to privatize the agency, a key Democratic senator said Tuesday, taking a stance on a politically charged issue that his predecessor says led to his firing.


Ex Input:
Paragraph: Fitness experts say users of the fitness machine, which is a favorite among Army Rangers, Navy Seals, and “The Biggest Loser” television series, reap total body, calorie-busting rewards. “It’s a great and tough cardio piece,” said Neal Pire, an exercise physiologist with the American College of Sports Medicine. “Picture a step mill that combines the lower and upper body, and you have Jacobs Ladder. Except instead of steps, you have rungs.”  Because the user climbs with arms as well as legs more muscles are working and more calories are burned. “As a rule the more muscle mass you utilize during any activity, the greater the oxygen consumed, which is directly correlated to the calories you consumed,” said Pire, president of Inspire Training Systems, in New Jersey. “Unlike stair climbers, you can’t hold on to the sides.”  Jacobs Ladder was invented by Steve Nichols, a fitness champion who injured his knees and back, according to Bob Palka, president of Jacobs Ladder, LLC. “He wanted to come up with a good workout that didn’t impact back and knees.” said Palka, who bought the patent and assets from Nichols in 1994. “Effectively it’s just climbing a ladder,” Palka said. People using the machine are placed at a 40-degree angle to put the spine in a more neutral position, relieve the back of stress and engage core muscles. Palka said on Jacobs Ladder the person’s body weight is lifted over a 12-inch (30.5-centemeter) step for fuller range of motion than the eight-inches of a step mill. “You control the speed,” he said.” The faster you go the faster the runners (on the ladder) come.”  Palka said about 50 to 60 percent of his Jacobs Ladders go to health clubs; some 10 to 15 percent go to the military and physical therapy facilities, respectively. Jacobs Ladder landed a recurring role on the TV show “The Biggest Loser” after trainer Jillian Michaels fell in love with it. “It tends to get your heart rate up,” said Palka, adding that other users, such as the FBI and the Army Rangers, are drawn to the intensity of the workout. John Trail, general manager of a Fitness First health club in Arlington, Virginia, uses Jacobs Ladder in functional circuit and interval training. “You can go for time or you can go for feet,” said Trail. “It’s not a fast-moving piece, but the fact that you’re using every muscle group means you can do 100 feet, rest, jump off, do 10 kettlebell swings, 10 short interval sprints, and burn a lot more calories than you would on an elliptical.”  Trail said a rock climbing buddy likes to climb Jacobs Ladder wearing a back pack for an endurance workout. A self-described competitive person, Trail has even raced with it. “We have two machines side-by-side, so we’ll go for 1,000 feet as fast as possible,” he said. “In under 10 minutes you can get a really good workout.”  He also uses it on clients with joint issues to get their heart rates up quickly. But despite its virtues, Pire said it’s unlikely Jacobs Ladder will supplant the treadmill anytime soon. “The tougher the machine, the more seldom you see it,” he said. “I haven’t seen many seniors hop on. The older population is concerned about balance and falling. And there’s some skill involved in climbing a ladder. But fans are ardent. “Those who use it are almost religious,” he said. Claim: Jacobs Ladder climbers reap tough fitness rewards.

Ex Output:
Jacobs Ladder, a moving, angled, climbing machine, may be named after the Biblical stairway to heaven, but it packs such a challenging workout people have dubbed it the stairway to hell.


Ex Input:
Paragraph: A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen’s version of AbbVie’s Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug. For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen’s drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients. But it could take years for those savings to arrive. Evercore ISI analyst Mark Schoenebaum says the earliest Amgen could launch its product would be March 2017, though that would risk infringing patents which Abbvie says protect its drug until at least 2022. Wall Street analysts expect the patent issue to be fought in court, and then for Amgen’s drug to launch sometime between 2018 and 2022. First approved in 2002, Humira has long been among the most profitable drugs in the world. It accounted for 60 percent of Abbvie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is approved for multiple uses, including rheumatoid arthritis, Crohn’s disease and psoriasis. Thousand Oaks, Calif-based Amgen is seeking FDA approval to market its version, known only as ABP 501, for seven diseases. Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales. The FDA only approved the first lower-cost biotech drug last March, a Novartis version of the Amgen drug Neupogen. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson’s Remicade, but it is not yet for sale. Questions remain about just how much savings U.S. biosimilars will deliver. Novartis’ Zarxio sells for 15 percent less than the original Neupogen. Experts predict biosimilar discounts of 15 percent to 30 percent in the U.S. In Europe, where governments regulate prices, discounts are higher. Development of lower-cost anti-inflammatory drugs like Humira is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. On Wednesday, the same panel of FDA advisers will review a Novartis version of Enbrel, which is marketed by Amgen. Claim: Lower-cost biotech drug gets thumbs up from FDA panel.

Ex Output:

The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.